Literature DB >> 26304558

BRIGHT HORIZONS for Bivalirudin? EUROMAXimizing benefits of bleeding risk but catching a MATRIX of HEAT for stent thrombosis.

Jonathan Soverow1, Ziad Ali2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26304558      PMCID： PMC4561783          DOI： 10.1016/j.ihj.2015.05.008

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


× No keyword cloud information.
  8 in total

1.  Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.

Authors:  Matthias Schwenkglenks; Toby J Toward; Stephanie Plent; Thomas D Szucs; Daniel J Blackman; Andreas Baumbach
Journal:  Heart       Date:  2012-02-07       Impact factor: 5.994

2.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

3.  Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.

Authors:  Eliano Pio Navarese; Volker Schulze; Felicita Andreotti; Mariusz Kowalewski; Michalina Kołodziejczak; David E Kandzari; Tienush Rassaf; Bartosz Gorny; Maximilian Brockmeyer; Christian Meyer; Sergio Berti; Jacek Kubica; Malte Kelm; Marco Valgimigli
Journal:  JACC Cardiovasc Interv       Date:  2014-11-01       Impact factor: 11.195

4.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Authors:  Yaling Han; Jincheng Guo; Yang Zheng; Hongyun Zang; Xi Su; Yu Wang; Shaoliang Chen; Tiemin Jiang; Ping Yang; Jiyan Chen; Dongju Jiang; Quanmin Jing; Zhenyang Liang; Haiwei Liu; Xin Zhao; Jing Li; Yi Li; Bo Xu; Gregg W Stone
Journal:  JAMA       Date:  2015-04-07       Impact factor: 56.272

Review 5.  Bivalirudin: a direct thrombin inhibitor.

Authors:  Timothy D Gladwell
Journal:  Clin Ther       Date:  2002-01       Impact factor: 3.393

6.  Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).

Authors:  Peter Clemmensen; Sebastian Wiberg; Arnoud Van't Hof; Efthymios N Deliargyris; Pierre Coste; Jurrien Ten Berg; Claudio Cavallini; Martial Hamon; Dariusz Dudek; Uwe Zeymer; Xavier Tabone; Steen D Kristensen; Debra Bernstein; Prodromos Anthopoulos; Jayne Prats; Philippe Gabriel Steg
Journal:  JACC Cardiovasc Interv       Date:  2015-01       Impact factor: 11.195

7.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

8.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

Authors:  Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables
Journal:  Lancet       Date:  2014-07-04       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.